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Abstract
Background: The rising incidence of melanoma – Switzerland has the highest incidence in Europe - is a major
public health challenge. Swiss dermatologist introduced the “Swiss Skin Cancer Day” (SSCD) in 2006, which provides
skin cancer screening at no costs. The aim of the study was to describe the participating subjects and their
motivation and investigate factors influencing the probability of a clinical diagnosis of skin malignancy.
Methods: 150 dermatologists were involved in the SSCD in May 2012. Dermatologists were not remunerated.
Participants had the opportunity to show a single skin lesion to a dermatologist at no cost. A questionnaire for
each participating subject collected data about subjects’ age, sex, risk factors and reason for encounter; furthermore
the dermatologist noted down clinical diagnosis and further management. We used descriptive statistics to report
characteristics of participants and skin lesions. We built two multiple logistic regression models, one regarding the
clinical diagnosis of skin malignancy and one regarding the further management.
Results: 5266 subjects (55.6% female) were assessed; in 308 (5.8%) participants a clinical diagnosis of skin
malignancy was found. In 1732 participants (32.9%) a clinical follow up or an excision was recommended. In the
multiple logistic regression model age, sex, skin phototype and the reason for participation at the SSCD were found
as significant risk factors regarding the clinical diagnosis of skin malignancy. Participants with skin cancer risk factors
were more likely to get a clinical follow up recommended even if the clinical diagnosis was benign.
Conclusion: A self-perceived suspicious lesion was the strongest predictor for a clinical diagnosis of skin malignancy at
the SSCD. This suggests that skin self-examination might also work in general population. Future research should focus
on better access to a specialist in case a suspicious skin lesion was discovered. Safety and quality of the SSCD should
be further investigated, especially concerning the discrepancy between the low number of malignant lesions and the
high quantity of participants where further clinical examinations or interventions were recommended.
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Background
The rising incidence of melanoma over the past decades is
a major public health challenge [1,2]. Switzerland (26.8
cases per 100’000 in male and 25.4 in female population;
European age-standardised rates) is among the countries
with the highest incidence [3]. Clinical examination of skin
does not require expensive technical equipment and early
detection of melanoma has a huge impact on prognosis
[4], thus cutaneous melanoma seems to be prone to
preventive services. While screening in high-risk patients
was shown to reduce mortality and to be cost-effective
[5,6], the evidence on effectiveness of screening pro-
grammes in general population remains inconclusive
[7-12]. German studies on a pilot in Schleswig-Holstein
and a consecutively introduced nationwide screening
programme produced promising results [10,13,14]. Com-
pared to the pre-screening era the mortality of melanoma
was reduced (from 1.9/100’000 to 1.0 in men and from 1.4
to 0.7 in women), while the mortality was stable in four
adjacent regions. Studies about the role of skin self-
examination (SSE) produced promising results: some* Correspondence: ryan.tandjung@usz.ch1Institute for Primary Care, University of Zurich, University Hospital of Zurich,
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studies showed that SSE reduces tumor thickness and
melanoma incidence in high-risk patients [15-18].
The Swiss healthcare system has no mandatory gate
keeping system. Dermatologists are working in outpatient
clinics as well as in private practices. Even though many
patients choose an insurance model without gatekeeping,
a direct consultation with a dermatologist is hardly pos-
sible and a referral from primary care physicians is usually
mandatory. Therefore a suspicious lesion in SSE might
have unnecessary barriers with a contact to a primary care
physician and a possible secondary referral to a derma-
tologist, since many primary care physicians also feel ra-
ther insecure concerning the diagnosis of melanoma [19].
Switzerland lacks a nationally coordinated cancer screen-
ing strategy, some prevention investigation such as a col-
onoscopy screening after the age of 50 have recently been
taken in the remuneration scheme of insurance companies.
A general skin cancer screening has not been implemented
so far, but local campaigns started in the late 80ies. The
evaluation of a skin cancer campaign in the year 2000
showed an important role of such campaigns in the early
detection of melanoma [20]. In 2006 a national and annual
prevention programme was introduced, when Switzerland
joined the European prevention campaign “Euromelanoma
Day”, where nowadays dermatologists of over 20 European
countries participate. The prevention campaign contains
both: a public health information campaign through mass
media about sun protection and the importance of an early
detection of melanoma and a special event, where anyone
can participate and will be examined by participating der-
matologists for free [21-23]. In Switzerland the prevention
campaign is called “Swiss Skin Cancer Day” (SSCD). Now-
adays, the SSCD is a multifaceted campaign with different
activities, such as public lectures about skin cancer, risk
factors for melanoma and the importance of an early de-
tection of melanoma; a media campaign concerning the
importance of sun protection and several other public
events. The main focus is on primary prevention, but
among these activities an opportunity of a free single skin
lesion check is offered to the public, which has to effects:
1) raising awareness for the importance of primary pre-
vention concerning skin cancer and 2) a possible early
detection of skin cancer (secondary prevention). In
times of scarce health professionals and rising health
care costs an implementation of a general screening
program might not be feasible. Therefore an event such
as the “Swiss Skin Cancer Day”, “Euromelanoma Day” or
“Melanoma Monday” in the US might also be effective
[21,24-27].
However two facts might limit the effect of such an
event: During the SSCD resources do not allow a full
body exam or the standardized use of dermoscopy, but
only an investigation of a single lesion. And second, pre-
vention campaigns are likely to reach a younger and
more health-conscious population and therefore might
not aim at the population most likely to profit [28,29].
Former SSCD participants stated different reasons for
their participation: while some subjects had a specific le-
sion they wanted to show to a dermatologist, others just
wanted to use the opportunity of a free skin check-up.
The aim of the study was to describe the participating
subjects and their motivation and investigate factors in-
fluencing the probability of a suspicion of malignancy.
Methods
Swiss skin cancer day
Among the activities of the SSCD, on special scheduled
slots dermatologists in private practices as well as out-
patient clinics offer the possibility to evaluate skin le-
sions of participants. Dermatologists in private practices
and Clinics of Dermatology had the freedom to partici-
pate or not; participation was not remunerated. On three
afternoons in May 2012 (7th, 9th and 12th) over 150 der-
matologists in the French and German speaking parts of
Switzerland offered such opportunities, all ten dermatol-
ogy clinics and 63 (out of 384) dermatologists in private
practice contributed to the SSCD 2012. For the patients
participation was free of charge and no special appoint-
ment was necessary. Participants had the possibility to
show a single skin lesion only; the logistic challenges –
mainly time constraints – did not allow a full body scan.
A dermoscopic investigation was allowed, although not
standardized and due to time constraints not routinely
offered and not documented.
Assessment instruments
We created a paper-based questionnaire collecting an-
onymous data about patient characteristics (sex, age, na-
tionality), main reason for participation on the SSCD
(specific lesion vs. general check-up vs. skin cancer of
friends), risk factors (Fitzpatrick phototype, over 100
nevi, skin cancer in family), and clinical diagnosis based
on the examination and recommendation for further
management. The further management was categorised
into three domains: 1) no further step necessary 2) clinical
observation and 3) excision or biopsy recommended. The
questionnaire was completely filled by the participating
dermatologists. Data management was centrally orga-
nized at the Institute for Primary Care of the University of
Zurich. A questionnaire is provided in Additional file 1.
We considered lentigo maligna, melanoma, basal cell
carcinoma, squamous cell carcinoma and “other malig-
nant diagnosis” as malignant.
Statistics
We used descriptive statistics to report characteristics of
participants and skin lesions. To compare male and fe-
male participants we used chi-square testing regarding
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the participants’ characteristics. We created a multiple
logistic regression to assess participants’ characteristics
(age, sex, reason for participation, more than 100 naevi,
skin phototype and family skin cancer history) associated
with a higher risk of a clinical diagnosis of skin malignancy.
Since we were specifically interested whether self-screening
was efficient, we created a dichotomous variable (1 = self-
perceived lesion, 0 = all other). We performed analyses
using Stata® Version 12.1 (Stata Corporation, College
Station, TX 77845, USA, www.stata.com). We regarded a
p < 0.01 as statistical significant.
We created a second multiple regression model con-
cerning further management. We excluded the partici-
pants with clinical malignant diagnosis. We grouped the
participants where a biopsy or excision and where a clin-
ical observation was recommended (biopsy or clinical
observation necessary = 1, no further investigation ne-
cessary = 0). Number of naevi, skin phototype, positive
family history and age were included in the regression
modell as influence factors.
Ethics approval
Under current ethical guidelines of the Swiss Academy
of Medical Sciences [30] this study collecting completely
anonymous data did not need formal ethical approval.
Data was treated confidentially. On a general information
letter of the SSCD activities participants were informed that
data collected would be analysed in anonymized form.
Results
During the three afternoons in May 2012, a total of 5266
subjects were screened (44.4% male, 55.6% female), the
average age was 51.2 years (SD 19.27) for male, and
48.1 years (SD 18.47) for female subjects (p = 0.224). The
prevalence of skin types was: Type I 323 (6.1%), Type II
2354 (44.7%), Type III 1734 (33.0%), Type IV 257 (4.9%),
Type V 45 (0.9%), Type VI 7 (0.1%), 546 entries were
missing. In the estimation of naevi 4090 (77.7%) had less
than 100 naevi, 613 (11.6%) more than 100; 563 data are
missing. 379 (7.2%) have a family history of skin cancer.
We asked subjects for their reason to participate. The
majority of 3178 subjects (60.4%) declared that they
wanted to use the possibility of a free check-up of the
skin. 1530 (29.1%) were using the possibility to show a
self-perceived suspicious skin lesion, 87 (1.7%) had skin
cancer cases in their entourage, 276 (5.25%) were sent
by their partners, 188 (3.6%) stated different or no rea-
sons. In Table 1 the risk factors are listed in female and
male participants.
In these 5266 subjects a total of 308 lesions had a clin-
ical diagnosis of skin malignancy: 38 were suspicious for
lentigo maligna, 34 for melanoma, 173 for basal cell car-
cinoma, 32 for squamous cell carcinoma and in 31 cases
another malignant lesion was suspected, details of clinically
diagnoses are shown in Table 2. In 3386 subjects (64.3%)
no further investigations were deemed required (= shown
skin lesion not suspicious for skin malignancy); in 968
(18.4%) a clinical follow-up assessment and in 764 (14.5%)
an excision or biopsy was recommended.
Detailed results of the multiple logistic regression
model concerning the probability of a clinical malignant
diagnosis are shown in Table 3. We found significant
Table 1 Characteristics of female and male participants
Female Male Significance level
Age in years (mean, SD) 48.1
(18.47)
51.2
(19.27)
p = 0.224
Skin phototype (%) P < 0.001
I 8.37 4.89
II 51.22 48.18
III 33.92 40.40
IV 5.25 5.71
V 1.06 0.77
VI 0.19 0.05
More than 100 naevi (%) 11.31 15.23 p < 0.001
Family history of
skin cancer (%)
8.27 5.87 p = 0.001
Reason for participation (%) p < 0.001
Checkup 63.15 57.03
Suspicious skin lesion 29.47 28.62
Skin cancer of friends 1.54 1.75
Sent by partner 9.55 1.81
Other 3.26 3.83
Numbers indicated age in years and all other variable indicate frequencies in
percentage of all female or male participants respectively. We used chi square
testing to compare the characteristics between male and female participants.
Table 2 Clinical classification of lesions
Clinical classification N %
Dermal nevus 1541 29.26%
Seborrhoic wart 1224 23.24%
Angioma 324 6.15%
other, benign 818 15.53%
Actinic keratosis 426 8.09%
Atypic nevus 450 8.55%
Lentigo maligna 38 0.72%
Melanoma 34 0.65%
Basal cell carcinoma 173 3.29%
Squamous cell carcinoma 32 0.61%
Other, malignant 31 0.59%
Not stated 175 3.32%
Total 5266 100%
For every participant only one lesion was documented.
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influencing factors were age, sex, reason for participation
and skin phototype. The results of the second multiple
regression model concerning further need of investiga-
tion (either biopsy/excision or clinical control) is shown
in Table 4. Participants with more than 100 naevi and a
positive family history were more likely to get a recom-
mendation for further investigations. To assess the risk
factors where dermatologists recommended further
management even though the clinical diagnosis was be-
nign, we created a multiple regression model.
Discussion
The attendance at the SSCD to show a self-perceived sus-
picious skin lesion was the strongest predictor in our mul-
tiple regression model (OR 1.6) for a clinical diagnosis of
skin malignancy. The national skin cancer campaign aims
at raising awareness for skin cancer, promoting sun pro-
tection and emphasising the importance of early detection.
This aim alone might already legitimate a prevention cam-
paign such as the SSCD. An easy access to a specialist in
case of a self-perceived abnormality of a skin lesion might
therefore be very helpful. Still whether SSCD is the right
instrument is questionable, doubts on safety and quality
regarding a single-lesion examination and no routine use
of dermoscopy remain and needs to be assessed in future
SSCD campaigns.
The uncertainty and limitations of the SSCD might
also be reflected in the discrepancy between the number
of clinical malignant diagnoses (5.8%) and the number of
participants, where a further workup (clinical observa-
tion or excision/biopsy) was recommended (32.9%). We
investigated possible reasons for this discrepancy in our
multiple regression model; participants with risk factors
were more likely to get a recommendation for further
workup, which could be explained by the context of the
SSCD, since participants were only allowed to show one
skin lesion. While this skin lesion was possibly benign,
the dermatologists nevertheless could have recom-
mended a dermatological consultation since he was not
able to conduct a complete dermatological workup. This
could raise awareness concerning the risk factors for
skin cancer and the importance of regular control in
participants with more risk factors, but the direct benefit
of the skin lesion screening remains questionable. For
clinics and private practices the event might also be an
incentive to attract future patients and therefore be a
useful public relations event; in case of a clinical uncer-
tainty this might also contribute to recommend a clinical
follow up rather than a reassurance.
Former studies have shown skin self-examination
(SSE) to be effective in high-risk patients [15-18]. Our
study suggests SSE might also work in a general popula-
tion. From a health services perspective this results implies
further research should focus on possibilities to allow an
easier access to a specialist, in case of self-perceived skin
lesion, especially outside such events. This also might re-
duce system delay from diagnosis to treatment [31].
Our analysis concerning clinical diagnosis of skin ma-
lignancy revealed an unexpected result regarding a positive
family history of skin cancer as a risk factor. Participants
with a positive family history had a lower risk of a clinical
diagnosis of skin malignancy than participants without.
Even though this result was statistically not significant in
our multiple logistic regression model, this finding raises
some questions about the study population. In our study
7.2% stated to have a family history for skin cancer. In the
evaluation of the Italian Euromelanoma campaign in
the years 2005–2007 7% of the participants recalled a
history of skin cancer and 5.2% of melanoma in a family
member [25]. The percentage was higher in the Swedish
Euromelanoma population, where 14.8% indicated a family
history of melanoma [24]; in the Swedish Euromelanoma
population the skin phototype were 32.9% with type II and
58.3% type III skin phototype, compared to 44.7% type II
and 33.0% type III in our population. One possible reason
Table 3 Multiple regression analysis, outcome clinical
malignancy
Odds ratio Standard error Significance
level
Sex 0.691 0.098 0.009
Age 1.049 0.005 <0.001
Number of Naevi 1.170 0.261 0.482
Skin phototype 0.629 0.066 <0.001
Reason for participation 1.658 0.235 <0.001
Family history 0.637 0.225 0.201
Multiple logistic regression analysis regarding influential factors concerning
clinical malignancy. Categories, reference value is indicated by a *(Sex 0 =
male*, 1 = female; age in years, 1 = *; Number of Naevi 0 = less than 100*, 1 =
more than 100; skin phototype Fitzpatrick types 1*-6; reason for participation
1 = self-perceived skin abnormality 0 = free skin checkup* and other reasons;
family history 1 = positive family history for skin cancer, *0 = no skin cancer in
family). Participants with missing data were excluded from this analysis, a total
of 4360 entries could be included in this model, R2 of this model = 0.11.
Table 4 Multiple regression analysis management
Odds ratio Standard error Significance level
Number of naevi 3.583 0.354 <0.001
Family history 1.406 0.191 0.012
Skin phototype 0.803 0.040 <0.001
Age 1.014 0.002 <0.001
Influence factors where further management was recommended despite a
bening clinical skin lesion. Reference value is indicated with * (Naevi: *0 = less
than 100 Naevi, 1 = more than 100 Naevi; Family history of skin cancer *0 = no,
1 = positive family history; skin phototype according to phototype 1 as
reference; age in years). Participants with clinical malignant diagnosis or
missing data were excluded from the analysis. 4062 entries were included in
this model; R2 of this model was 0.0493.
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for this finding could therefore be an incomplete reporting
of family history in the participants’ questionnaire and the
result might be biased. Another reason could be that per-
sons with family history were possibly already under regu-
lar skin control and therefore did not participate at the
SSCD.
Strength and limitations
In our study with the complete dataset on subjects par-
ticipating on the “Swiss Skin Cancer Day” in 2012, we
could show that SSE seems to ameliorate effectiveness of
screening and raise the detection rate of clinical diagno-
ses of skin malignancies. These results are limited by the
fact than only single lesions were assessed during the
event. Furthermore in our study we were only able to in-
clude clinical diagnosis and could not confirm the diag-
noses either by dermoscopy or histological findings, this
could possibly lead to an overdiagnosis. Also recommen-
dations for a clinical control and/or an excision of the
skin lesions were in very high, we do not know what the
reasons are for that high number and how many patients
really participated in a follow up.
Conclusion
A self-perceived suspicious lesion was the strongest pre-
dictor for a clinical diagnosis of skin malignancy at the
SSCD. This suggests that skin self-examination might
also work in general population. Future research should
focus on better access to a specialist in case a suspicious
skin lesion was discovered. Safety and quality of the SSCD
should be further investigated, especially concerning the
discrepancy between the low number of malignant lesions
and the high quantity of participants where further clinical
examinations or interventions were recommended.
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